<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03851419</url>
  </required_header>
  <id_info>
    <org_study_id>CYSTINET-Africa Tz II</org_study_id>
    <nct_id>NCT03851419</nct_id>
  </id_info>
  <brief_title>The Burden of (Neuro)Cysticercosis Among People Living With HIV in Rural Tanzania</brief_title>
  <acronym>CYSTINET_Tz</acronym>
  <official_title>The Burden of (Neuro)Cysticercosis Among People Living With HIV Compared With HIV-negative Individuals in the Rural Southern Highlands in Tanzania</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universit채t M체nchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute for Medical Research, Tanzania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kilimanjaro Clinical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Muhimbili University of Health and Allied Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universit채t M체nchen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare the burden of neurocysticercosis among people living with HIV to
      people not infected with HIV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      People living with HIV and matched HIV negative controls will be tested serologically for
      cysticercosis, examined neurologically and will undergo CT scanning to determine the
      prevalence and presentation of NCC.

      Furthermore, the immune system response in HIV patients with Taenia solium neurocysticercosis
      will be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of cysticercosis</measure>
    <time_frame>Single assessment at inclusion into study (serological testing)</time_frame>
    <description>Prevalence of cysticercosis among people living with HIV and matched HIV-negative individuals in rural Tanzania where pig farming is common</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of neurocysticercosis</measure>
    <time_frame>Single assessment through cerebral CT scan at inclusion into study</time_frame>
    <description>Prevalence of neurocysticercosis among people living with HIV and matched HIV-negative individuals in rural Tanzania where pig farming is common</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Th1 cytokines among neurocysticercosis patients</measure>
    <time_frame>One time assessment through immunological testing at inclusion into study</time_frame>
    <description>To compare the specific peripheral immune response against T. solium neurocysticercosis between symptomatic and asymptomatic patients measured by concentration of Th1 cytokines.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Neurocysticercosis</condition>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>People living with HIV</arm_group_label>
    <description>People living with HIV (ART naive or on ART)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>People not infected with HIV</arm_group_label>
    <description>HIV-negative people. Each participant is matched for age, sex and location to a study participant living with HIV</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Diagnosis of (Neuro)cysticercosis</intervention_name>
    <description>Serological tests for cysticercosis
Neurological examination and cerebral CT scan for the diagnosis of neurocysticercosis
Stool testing for T. solium</description>
    <arm_group_label>People living with HIV</arm_group_label>
    <arm_group_label>People not infected with HIV</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1000 patients from HIV clinics will be recruited at the study sites in Mbeya and Iringa
        region. For each HIV-positive patient an HIV-negative control matched by age, sex and
        location will be included.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who consent to participate in the study and testing.

          -  Patients of age 14 years and above

          -  Patient living inside the study catchment area

          -  HIV-positive patients

          -  Patient suspected of taeniasis or cysticercosis/neurocysticercosis

        Exclusion Criteria:

          -  Patients with opportunistic infections.

          -  Study participants taking anthelminthic drugs PZQ and ALB or have received them within
             the previous 12 months.

          -  Pregnant women

          -  Patients that are seriously ill.

          -  Patients with epilepsy and other mental disorders that impair thoughts and emotions
             such as psychosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard J Ngowi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute for Medical Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bernard J Ngowi, MD, PhD</last_name>
    <phone>+255 7639 18181</phone>
    <email>b_ngowi@yahoo.co.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea S Winkler, MD, PhD</last_name>
    <phone>+49 89 4140</phone>
    <phone_ext>9210</phone_ext>
    <email>andrea.winkler@tum.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institute of Medical Research</name>
      <address>
        <city>Dar Es Salaam</city>
        <country>Tanzania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard J Ngowi, MD, PhD</last_name>
      <phone>+255 763 918181</phone>
      <email>b_ngowi@yahoo.co.uk</email>
    </contact>
    <contact_backup>
      <last_name>Andrea S Winkler, MD, PhD</last_name>
      <phone>+49 89 4140</phone>
      <phone_ext>9210</phone_ext>
      <email>andrea.winkler@tum.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Tanzania</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>February 4, 2019</study_first_submitted>
  <study_first_submitted_qc>February 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2019</study_first_posted>
  <last_update_submitted>February 28, 2019</last_update_submitted>
  <last_update_submitted_qc>February 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurocysticercosis</mesh_term>
    <mesh_term>Cysticercosis</mesh_term>
    <mesh_term>Taeniasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

